Global Gene Editing Safety Assessment Services Market 2026 by Company, Regions, Type and Application, Forecast to 2032

September 2026 | 110 pages | ID: G804EE9375FDEN
GlobalInfoResearch

Abstracts

According to our (Global Info Research) latest study, the global Gene Editing Safety Assessment Services market size was valued at US$ 327 million in 2025 and is forecast to a readjusted size of US$ 1038 million by 2032 with a CAGR of 17.8% during review period.

Gene editing safety assessment services refer to third-party research, analytical testing, bioinformatics, and regulatory-support activities used to characterize the safety and genomic consequences of engineered edits in cells, tissues, animals, and clinical samples. The service scope centers on in silico risk screening, empirical off-target site nomination, targeted confirmation, on-target edit outcome characterization, detection of translocations and other structural variants, genome integrity analysis, biodistribution and tissue editing measurement, tumorigenicity or functional safety testing, and regulatory-ready interpretation. Typical workflows combine targeted amplicon sequencing, short- and long-read whole-genome sequencing, unbiased break-site mapping, cytogenetic assays, PCR, multi-omics, and validated bioinformatics, with study design adapted to nuclease, base-editing, prime-editing, and multiplex-editing systems. Customers primarily purchase stand-alone assays or integrated packages spanning discovery, lead optimization, preclinical development, IND-enabling studies, and clinical follow-up. The blended gross margin is approximately 55%.

Market Trends

The industry is moving from limited validation of predicted loci toward orthogonal workflows that combine computational screening, unbiased cell-based or biochemical nomination, targeted deep confirmation, and structural-variant assessment. Short-read sequencing remains the main platform for scalable quantification and confirmation, while long-read sequencing is increasingly used to resolve complex rearrangements, large deletions, and insertions. Dedicated workflows are also emerging for base editors, prime editors, multiplex editing, and different delivery systems. Customers increasingly evaluate providers on access to relevant cell models, sensitivity for low-frequency events, coverage of donor and population variation, method-validation status, data traceability, and regulatory-reporting experience, shifting demand from stand-alone sequencing toward integrated safety programs.

Drivers

As gene editing pipelines advance into preclinical and clinical development, candidate-editor screening, off-target risk control, genome integrity assessment, and long-term safety monitoring are becoming mandatory budget items. More specific regulatory expectations for product design, manufacturing testing, nonclinical safety, and clinical follow-up are expanding the required evidence package. In vivo editing and allogeneic cell therapy add demand for tissue distribution, immune-response, and complex-rearrangement assessment, increasing both the breadth and technical depth of outsourced studies.

Restraints

Safety studies often require therapeutically relevant cells, multiple donors, matched controls, and high sequencing depth, making sample preparation and method development difficult to standardize. Some low-frequency events approach platform noise limits, while complex genomic regions, clonal selection, and cell culture can introduce background variants. These factors raise project cost and duration and require sponsors to reserve adequate material, controls, and validation budgets early in development.

Opportunities

Base editing, prime editing, multiplex editing, and individualized products create new analytical requirements for RNA off-target effects, non-double-strand-break editing outcomes, population variation, and complex structural events. Providers that integrate editing-system design, sample processing, unbiased nomination, confirmation testing, whole-genome integrity analysis, toxicology, and regulatory reporting within one project framework can reduce inter-laboratory variability and duplicate validation, capturing a larger share of program value.

Challenges

The sector still lacks fully harmonized assay combinations, positivity thresholds, and standards for interpreting biological risk, and results may vary across platforms, experimental conditions, and bioinformatics pipelines. Providers must also respond to rapid editor innovation, updates to reference genomes and variant databases, data-security obligations, and cross-regional compliance requirements while avoiding the assumption that every detectable molecular event represents a confirmed clinical hazard.

Value Chain Analysis

Upstream inputs include short- and long-read sequencing platforms, PCR and cytogenetic instruments, library-preparation reagents, reference materials, cell models, reference genomes, and analytical software. Midstream providers design studies, process samples, nominate and confirm sites, analyze data, manage quality, and prepare regulatory-ready reports. Downstream customers include gene and cell therapy developers, pharmaceutical and biotechnology companies, research institutions, and other industries using genome editing. The principal value is not raw sequencing output but an evidence chain connecting editing mechanism, sample background, detection limits, structural variation, and biological impact to candidate selection and regulatory communication. Major costs arise from deep sequencing, specialized reagents, scientific labor, bioinformatics, quality systems, and project management, while proprietary methods, validated workflows, and regulatory experience determine pricing power and margin.

Segment Insights

By service scope, off-target nomination and confirmation remain the demand foundation and are commonly purchased together with on-target outcome and structural-variant assessment. Integrated safety packages carry higher project values and stronger growth as candidates approach regulatory submission. By technology, targeted amplicon sequencing retains a central role because of its depth, cost, and throughput; unbiased cell-based or biochemical break mapping supports site nomination; short-read whole-genome sequencing broadens variant screening; and long-read platforms are gaining use for complex rearrangements and difficult genomic regions. Preclinical and IND-enabling studies concentrate the highest-value work because they require stronger method performance, quality controls, and reporting completeness.

Downstream Market Opportunities

Ex vivo edited cell therapies are the most established demand source because samples are accessible and editing sites and cellular backgrounds are comparatively well defined, enabling systematic nomination and confirmation. In vivo genome editing offers faster opportunity growth but requires more complex evaluation of tissue distribution, delivery systems, immune responses, low-frequency tissue editing, and long-term effects. Drug discovery, disease modeling, and basic research are more sensitive to price and turnaround time, while agricultural and industrial biotechnology emphasize trait stability, unintended variation, and compatibility with diverse reference genomes.

Regional Insights

North America has the densest concentration of therapeutic genome editing companies, specialized analytical platforms, and regulatory-submission experience, making it the principal region for high-value outsourcing and commercialization of new assays. Europe has strong capabilities in cell therapy, genomics, and quality systems, with customers placing greater emphasis on multi-region filing compatibility and data governance. Asia Pacific is expanding through biopharmaceutical investment, growing clinical activity, and local laboratory capacity in China, Japan, South Korea, and Singapore. However, complex unbiased testing and integrated regulatory packages remain concentrated among a limited number of platforms, creating opportunities for cross-border partnerships and localized validation.

Competitive Landscape Analysis

The market combines specialized technology platforms with integrated CROs. Specialist providers differentiate through proprietary nomination methods, variant-aware analysis, break-site mapping, or structural-rearrangement assays and often build strong technical retention in early editor selection and high-sensitivity genomic risk assessment. Large CROs and global testing groups compete through GLP or GxP systems, animal studies, clinical-sample networks, toxicology, and regulatory delivery across multiple development stages. Competition is shifting from isolated assay performance toward orthogonal method portfolios, relevant-cell handling, validation, integrated data interpretation, and submission-ready reporting. Partnerships, licensing, and acquisitions are increasingly used to connect editing tools, analytical assays, and broader safety-development capabilities.

Report Scope

This report is a detailed and comprehensive analysis for global Gene Editing Safety Assessment Services market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Gene Editing Safety Assessment Services market size and forecasts, in consumption value ($ Million), 2021-2032

Global Gene Editing Safety Assessment Services market size and forecasts by region and country, in consumption value ($ Million), 2021-2032

Global Gene Editing Safety Assessment Services market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032

Global Gene Editing Safety Assessment Services market shares of main players, in revenue ($ Million), 2021-2026

The Primary Objectives in This Report Are:

• To determine the size of the total market opportunity of global and key countries
• To assess the growth potential for Gene Editing Safety Assessment Services
• To forecast future growth in each product and end-use market
• To assess competitive factors affecting the marketplace

This report profiles key players in the global Gene Editing Safety Assessment Services market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Integrated DNA Technologies, MaxCyte, Avance Biosciences, Broken String Biosciences, Synthego, GenScript, CD Genomics, Creative Biogene, Labcorp, Charles River Laboratories, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Gene Editing Safety Assessment Services market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation

Market segment by Type

• Discovery Screening
• Lead Optimization
• Preclinical Development
• IND-Enabling Studies
• Clinical Development
• Commercial and Lifecycle Support

Market segment by Primary Technology Platform

• In Silico Risk Prediction
• Targeted Amplicon Sequencing
• Genome-Wide Sequencing
• Cytogenetic and Functional Assays
• Unbiased Break-Site Mapping

Market segment by Sample Source

• Established Cell Lines
• Primary Somatic Cells
• Stem and Progenitor Cells
• Animal Tissues
• Clinical Specimens
• Other Biological Samples

Market segment by Application

• Biopharmaceutical and Cell & Gene Therapy Companies
• Clinical and Independent Testing Laboratories
• Academic and Government Research Institutes
• Agricultural Biotechnology Companies
• Industrial Biotechnology Companies

Market segment by players, this report covers

• Integrated DNA Technologies
• MaxCyte
• Avance Biosciences
• Broken String Biosciences
• Synthego
• GenScript
• CD Genomics
• Creative Biogene
• Labcorp
• Charles River Laboratories
• BioAgilytix
• Precision for Medicine
• Franklin Bio
• Eurofins Scientific
• SGS

Market segment by regions, regional analysis covers

• North America (United States, Canada and Mexico)
• Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
• South America (Brazil, Rest of South America)
• Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Chapter Outline

Chapter 1, to describe Gene Editing Safety Assessment Services product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Gene Editing Safety Assessment Services, with revenue, gross margin, and global market share of Gene Editing Safety Assessment Services from 2021 to 2026.

Chapter 3, the Gene Editing Safety Assessment Services competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Gene Editing Safety Assessment Services market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Editing Safety Assessment Services.

Chapter 13, to describe Gene Editing Safety Assessment Services research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Gene Editing Safety Assessment Services by Type
  1.3.1 Overview: Global Gene Editing Safety Assessment Services Market Size by Type: 2021 Versus 2025 Versus 2032
  1.3.2 Global Gene Editing Safety Assessment Services Consumption Value Market Share by Type in 2025
  1.3.3 Discovery Screening
  1.3.4 Lead Optimization
  1.3.5 Preclinical Development
  1.3.6 IND-Enabling Studies
  1.3.7 Clinical Development
  1.3.8 Commercial and Lifecycle Support
1.4 Classification of Gene Editing Safety Assessment Services by Primary Technology Platform
  1.4.1 Overview: Global Gene Editing Safety Assessment Services Market Size by Primary Technology Platform: 2021 Versus 2025 Versus 2032
  1.4.2 Global Gene Editing Safety Assessment Services Consumption Value Market Share by Primary Technology Platform in 2025
  1.4.3 In Silico Risk Prediction
  1.4.4 Targeted Amplicon Sequencing
  1.4.5 Genome-Wide Sequencing
  1.4.6 Cytogenetic and Functional Assays
  1.4.7 Unbiased Break-Site Mapping
1.5 Classification of Gene Editing Safety Assessment Services by Sample Source
  1.5.1 Overview: Global Gene Editing Safety Assessment Services Market Size by Sample Source: 2021 Versus 2025 Versus 2032
  1.5.2 Global Gene Editing Safety Assessment Services Consumption Value Market Share by Sample Source in 2025
  1.5.3 Established Cell Lines
  1.5.4 Primary Somatic Cells
  1.5.5 Stem and Progenitor Cells
  1.5.6 Animal Tissues
  1.5.7 Clinical Specimens
  1.5.8 Other Biological Samples
1.6 Global Gene Editing Safety Assessment Services Market by Application
  1.6.1 Overview: Global Gene Editing Safety Assessment Services Market Size by Application: 2021 Versus 2025 Versus 2032
  1.6.2 Biopharmaceutical and Cell & Gene Therapy Companies
  1.6.3 Clinical and Independent Testing Laboratories
  1.6.4 Academic and Government Research Institutes
  1.6.5 Agricultural Biotechnology Companies
  1.6.6 Industrial Biotechnology Companies
1.7 Global Gene Editing Safety Assessment Services Market Size & Forecast
1.8 Global Gene Editing Safety Assessment Services Market Size and Forecast by Region
  1.8.1 Global Gene Editing Safety Assessment Services Market Size by Region: 2021 VS 2025 VS 2032
  1.8.2 Global Gene Editing Safety Assessment Services Market Size by Region, (2021-2032)
  1.8.3 North America Gene Editing Safety Assessment Services Market Size and Prospect (2021-2032)
  1.8.4 Europe Gene Editing Safety Assessment Services Market Size and Prospect (2021-2032)
  1.8.5 Asia-Pacific Gene Editing Safety Assessment Services Market Size and Prospect (2021-2032)
  1.8.6 South America Gene Editing Safety Assessment Services Market Size and Prospect (2021-2032)
  1.8.7 Middle East & Africa Gene Editing Safety Assessment Services Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 Integrated DNA Technologies
  2.1.1 Integrated DNA Technologies Details
  2.1.2 Integrated DNA Technologies Major Business
  2.1.3 Integrated DNA Technologies Gene Editing Safety Assessment Services Product and Solutions
  2.1.4 Integrated DNA Technologies Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.1.5 Integrated DNA Technologies Recent Developments and Future Plans
2.2 MaxCyte
  2.2.1 MaxCyte Details
  2.2.2 MaxCyte Major Business
  2.2.3 MaxCyte Gene Editing Safety Assessment Services Product and Solutions
  2.2.4 MaxCyte Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.2.5 MaxCyte Recent Developments and Future Plans
2.3 Avance Biosciences
  2.3.1 Avance Biosciences Details
  2.3.2 Avance Biosciences Major Business
  2.3.3 Avance Biosciences Gene Editing Safety Assessment Services Product and Solutions
  2.3.4 Avance Biosciences Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.3.5 Avance Biosciences Recent Developments and Future Plans
2.4 Broken String Biosciences
  2.4.1 Broken String Biosciences Details
  2.4.2 Broken String Biosciences Major Business
  2.4.3 Broken String Biosciences Gene Editing Safety Assessment Services Product and Solutions
  2.4.4 Broken String Biosciences Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.4.5 Broken String Biosciences Recent Developments and Future Plans
2.5 Synthego
  2.5.1 Synthego Details
  2.5.2 Synthego Major Business
  2.5.3 Synthego Gene Editing Safety Assessment Services Product and Solutions
  2.5.4 Synthego Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.5.5 Synthego Recent Developments and Future Plans
2.6 GenScript
  2.6.1 GenScript Details
  2.6.2 GenScript Major Business
  2.6.3 GenScript Gene Editing Safety Assessment Services Product and Solutions
  2.6.4 GenScript Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.6.5 GenScript Recent Developments and Future Plans
2.7 CD Genomics
  2.7.1 CD Genomics Details
  2.7.2 CD Genomics Major Business
  2.7.3 CD Genomics Gene Editing Safety Assessment Services Product and Solutions
  2.7.4 CD Genomics Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.7.5 CD Genomics Recent Developments and Future Plans
2.8 Creative Biogene
  2.8.1 Creative Biogene Details
  2.8.2 Creative Biogene Major Business
  2.8.3 Creative Biogene Gene Editing Safety Assessment Services Product and Solutions
  2.8.4 Creative Biogene Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.8.5 Creative Biogene Recent Developments and Future Plans
2.9 Labcorp
  2.9.1 Labcorp Details
  2.9.2 Labcorp Major Business
  2.9.3 Labcorp Gene Editing Safety Assessment Services Product and Solutions
  2.9.4 Labcorp Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.9.5 Labcorp Recent Developments and Future Plans
2.10 Charles River Laboratories
  2.10.1 Charles River Laboratories Details
  2.10.2 Charles River Laboratories Major Business
  2.10.3 Charles River Laboratories Gene Editing Safety Assessment Services Product and Solutions
  2.10.4 Charles River Laboratories Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.10.5 Charles River Laboratories Recent Developments and Future Plans
2.11 BioAgilytix
  2.11.1 BioAgilytix Details
  2.11.2 BioAgilytix Major Business
  2.11.3 BioAgilytix Gene Editing Safety Assessment Services Product and Solutions
  2.11.4 BioAgilytix Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.11.5 BioAgilytix Recent Developments and Future Plans
2.12 Precision for Medicine
  2.12.1 Precision for Medicine Details
  2.12.2 Precision for Medicine Major Business
  2.12.3 Precision for Medicine Gene Editing Safety Assessment Services Product and Solutions
  2.12.4 Precision for Medicine Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.12.5 Precision for Medicine Recent Developments and Future Plans
2.13 Franklin Bio
  2.13.1 Franklin Bio Details
  2.13.2 Franklin Bio Major Business
  2.13.3 Franklin Bio Gene Editing Safety Assessment Services Product and Solutions
  2.13.4 Franklin Bio Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.13.5 Franklin Bio Recent Developments and Future Plans
2.14 Eurofins Scientific
  2.14.1 Eurofins Scientific Details
  2.14.2 Eurofins Scientific Major Business
  2.14.3 Eurofins Scientific Gene Editing Safety Assessment Services Product and Solutions
  2.14.4 Eurofins Scientific Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.14.5 Eurofins Scientific Recent Developments and Future Plans
2.15 SGS
  2.15.1 SGS Details
  2.15.2 SGS Major Business
  2.15.3 SGS Gene Editing Safety Assessment Services Product and Solutions
  2.15.4 SGS Gene Editing Safety Assessment Services Revenue, Gross Margin and Market Share (2021-2026)
  2.15.5 SGS Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Gene Editing Safety Assessment Services Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
  3.2.1 Market Share of Gene Editing Safety Assessment Services by Company Revenue
  3.2.2 Top 3 Gene Editing Safety Assessment Services Players Market Share in 2025
  3.2.3 Top 6 Gene Editing Safety Assessment Services Players Market Share in 2025
3.3 Gene Editing Safety Assessment Services Market: Overall Company Footprint Analysis
  3.3.1 Gene Editing Safety Assessment Services Market: Region Footprint
  3.3.2 Gene Editing Safety Assessment Services Market: Company Product Type Footprint
  3.3.3 Gene Editing Safety Assessment Services Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Gene Editing Safety Assessment Services Consumption Value and Market Share by Type (2021-2026)
4.2 Global Gene Editing Safety Assessment Services Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Gene Editing Safety Assessment Services Consumption Value Market Share by Application (2021-2026)
5.2 Global Gene Editing Safety Assessment Services Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America Gene Editing Safety Assessment Services Consumption Value by Type (2021-2032)
6.2 North America Gene Editing Safety Assessment Services Market Size by Application (2021-2032)
6.3 North America Gene Editing Safety Assessment Services Market Size by Country
  6.3.1 North America Gene Editing Safety Assessment Services Consumption Value by Country (2021-2032)
  6.3.2 United States Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  6.3.3 Canada Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  6.3.4 Mexico Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe Gene Editing Safety Assessment Services Consumption Value by Type (2021-2032)
7.2 Europe Gene Editing Safety Assessment Services Consumption Value by Application (2021-2032)
7.3 Europe Gene Editing Safety Assessment Services Market Size by Country
  7.3.1 Europe Gene Editing Safety Assessment Services Consumption Value by Country (2021-2032)
  7.3.2 Germany Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  7.3.3 France Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  7.3.4 United Kingdom Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  7.3.5 Russia Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  7.3.6 Italy Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Gene Editing Safety Assessment Services Market Size by Region
  8.3.1 Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Region (2021-2032)
  8.3.2 China Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  8.3.3 Japan Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  8.3.4 South Korea Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  8.3.5 India Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  8.3.6 Southeast Asia Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  8.3.7 Australia Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America Gene Editing Safety Assessment Services Consumption Value by Type (2021-2032)
9.2 South America Gene Editing Safety Assessment Services Consumption Value by Application (2021-2032)
9.3 South America Gene Editing Safety Assessment Services Market Size by Country
  9.3.1 South America Gene Editing Safety Assessment Services Consumption Value by Country (2021-2032)
  9.3.2 Brazil Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  9.3.3 Argentina Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Gene Editing Safety Assessment Services Market Size by Country
  10.3.1 Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Country (2021-2032)
  10.3.2 Turkey Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  10.3.3 Saudi Arabia Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)
  10.3.4 UAE Gene Editing Safety Assessment Services Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 Gene Editing Safety Assessment Services Market Drivers
11.2 Gene Editing Safety Assessment Services Market Restraints
11.3 Gene Editing Safety Assessment Services Trends Analysis
11.4 Porters Five Forces Analysis
  11.4.1 Threat of New Entrants
  11.4.2 Bargaining Power of Suppliers
  11.4.3 Bargaining Power of Buyers
  11.4.4 Threat of Substitutes
  11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Gene Editing Safety Assessment Services Industry Chain
12.2 Gene Editing Safety Assessment Services Upstream Analysis
12.3 Gene Editing Safety Assessment Services Midstream Analysis
12.4 Gene Editing Safety Assessment Services Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Gene Editing Safety Assessment Services Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Gene Editing Safety Assessment Services Consumption Value by Primary Technology Platform, (USD Million), 2021 & 2025 & 2032
Table 3. Global Gene Editing Safety Assessment Services Consumption Value by Sample Source, (USD Million), 2021 & 2025 & 2032
Table 4. Global Gene Editing Safety Assessment Services Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Gene Editing Safety Assessment Services Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Gene Editing Safety Assessment Services Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Integrated DNA Technologies Company Information, Head Office, and Major Competitors
Table 8. Integrated DNA Technologies Major Business
Table 9. Integrated DNA Technologies Gene Editing Safety Assessment Services Product and Solutions
Table 10. Integrated DNA Technologies Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Integrated DNA Technologies Recent Developments and Future Plans
Table 12. MaxCyte Company Information, Head Office, and Major Competitors
Table 13. MaxCyte Major Business
Table 14. MaxCyte Gene Editing Safety Assessment Services Product and Solutions
Table 15. MaxCyte Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. MaxCyte Recent Developments and Future Plans
Table 17. Avance Biosciences Company Information, Head Office, and Major Competitors
Table 18. Avance Biosciences Major Business
Table 19. Avance Biosciences Gene Editing Safety Assessment Services Product and Solutions
Table 20. Avance Biosciences Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. Broken String Biosciences Company Information, Head Office, and Major Competitors
Table 22. Broken String Biosciences Major Business
Table 23. Broken String Biosciences Gene Editing Safety Assessment Services Product and Solutions
Table 24. Broken String Biosciences Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. Broken String Biosciences Recent Developments and Future Plans
Table 26. Synthego Company Information, Head Office, and Major Competitors
Table 27. Synthego Major Business
Table 28. Synthego Gene Editing Safety Assessment Services Product and Solutions
Table 29. Synthego Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Synthego Recent Developments and Future Plans
Table 31. GenScript Company Information, Head Office, and Major Competitors
Table 32. GenScript Major Business
Table 33. GenScript Gene Editing Safety Assessment Services Product and Solutions
Table 34. GenScript Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. GenScript Recent Developments and Future Plans
Table 36. CD Genomics Company Information, Head Office, and Major Competitors
Table 37. CD Genomics Major Business
Table 38. CD Genomics Gene Editing Safety Assessment Services Product and Solutions
Table 39. CD Genomics Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. CD Genomics Recent Developments and Future Plans
Table 41. Creative Biogene Company Information, Head Office, and Major Competitors
Table 42. Creative Biogene Major Business
Table 43. Creative Biogene Gene Editing Safety Assessment Services Product and Solutions
Table 44. Creative Biogene Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Creative Biogene Recent Developments and Future Plans
Table 46. Labcorp Company Information, Head Office, and Major Competitors
Table 47. Labcorp Major Business
Table 48. Labcorp Gene Editing Safety Assessment Services Product and Solutions
Table 49. Labcorp Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. Labcorp Recent Developments and Future Plans
Table 51. Charles River Laboratories Company Information, Head Office, and Major Competitors
Table 52. Charles River Laboratories Major Business
Table 53. Charles River Laboratories Gene Editing Safety Assessment Services Product and Solutions
Table 54. Charles River Laboratories Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Charles River Laboratories Recent Developments and Future Plans
Table 56. BioAgilytix Company Information, Head Office, and Major Competitors
Table 57. BioAgilytix Major Business
Table 58. BioAgilytix Gene Editing Safety Assessment Services Product and Solutions
Table 59. BioAgilytix Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 60. BioAgilytix Recent Developments and Future Plans
Table 61. Precision for Medicine Company Information, Head Office, and Major Competitors
Table 62. Precision for Medicine Major Business
Table 63. Precision for Medicine Gene Editing Safety Assessment Services Product and Solutions
Table 64. Precision for Medicine Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 65. Precision for Medicine Recent Developments and Future Plans
Table 66. Franklin Bio Company Information, Head Office, and Major Competitors
Table 67. Franklin Bio Major Business
Table 68. Franklin Bio Gene Editing Safety Assessment Services Product and Solutions
Table 69. Franklin Bio Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 70. Franklin Bio Recent Developments and Future Plans
Table 71. Eurofins Scientific Company Information, Head Office, and Major Competitors
Table 72. Eurofins Scientific Major Business
Table 73. Eurofins Scientific Gene Editing Safety Assessment Services Product and Solutions
Table 74. Eurofins Scientific Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 75. Eurofins Scientific Recent Developments and Future Plans
Table 76. SGS Company Information, Head Office, and Major Competitors
Table 77. SGS Major Business
Table 78. SGS Gene Editing Safety Assessment Services Product and Solutions
Table 79. SGS Gene Editing Safety Assessment Services Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 80. SGS Recent Developments and Future Plans
Table 81. Global Gene Editing Safety Assessment Services Revenue (USD Million) by Players (2021-2026)
Table 82. Global Gene Editing Safety Assessment Services Revenue Share by Players (2021-2026)
Table 83. Breakdown of Gene Editing Safety Assessment Services by Company Type (Tier 1, Tier 2, and Tier 3)
Table 84. Market Position of Players in Gene Editing Safety Assessment Services, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 85. Head Office of Key Gene Editing Safety Assessment Services Players
Table 86. Gene Editing Safety Assessment Services Market: Company Product Type Footprint
Table 87. Gene Editing Safety Assessment Services Market: Company Product Application Footprint
Table 88. Gene Editing Safety Assessment Services New Market Entrants and Barriers to Market Entry
Table 89. Gene Editing Safety Assessment Services Mergers, Acquisition, Agreements, and Collaborations
Table 90. Global Gene Editing Safety Assessment Services Consumption Value (USD Million) by Type (2021-2026)
Table 91. Global Gene Editing Safety Assessment Services Consumption Value Share by Type (2021-2026)
Table 92. Global Gene Editing Safety Assessment Services Consumption Value Forecast by Type (2027-2032)
Table 93. Global Gene Editing Safety Assessment Services Consumption Value by Application (2021-2026)
Table 94. Global Gene Editing Safety Assessment Services Consumption Value Forecast by Application (2027-2032)
Table 95. North America Gene Editing Safety Assessment Services Consumption Value by Type (2021-2026) & (USD Million)
Table 96. North America Gene Editing Safety Assessment Services Consumption Value by Type (2027-2032) & (USD Million)
Table 97. North America Gene Editing Safety Assessment Services Consumption Value by Application (2021-2026) & (USD Million)
Table 98. North America Gene Editing Safety Assessment Services Consumption Value by Application (2027-2032) & (USD Million)
Table 99. North America Gene Editing Safety Assessment Services Consumption Value by Country (2021-2026) & (USD Million)
Table 100. North America Gene Editing Safety Assessment Services Consumption Value by Country (2027-2032) & (USD Million)
Table 101. Europe Gene Editing Safety Assessment Services Consumption Value by Type (2021-2026) & (USD Million)
Table 102. Europe Gene Editing Safety Assessment Services Consumption Value by Type (2027-2032) & (USD Million)
Table 103. Europe Gene Editing Safety Assessment Services Consumption Value by Application (2021-2026) & (USD Million)
Table 104. Europe Gene Editing Safety Assessment Services Consumption Value by Application (2027-2032) & (USD Million)
Table 105. Europe Gene Editing Safety Assessment Services Consumption Value by Country (2021-2026) & (USD Million)
Table 106. Europe Gene Editing Safety Assessment Services Consumption Value by Country (2027-2032) & (USD Million)
Table 107. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Type (2021-2026) & (USD Million)
Table 108. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Type (2027-2032) & (USD Million)
Table 109. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Application (2021-2026) & (USD Million)
Table 110. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Application (2027-2032) & (USD Million)
Table 111. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Region (2021-2026) & (USD Million)
Table 112. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value by Region (2027-2032) & (USD Million)
Table 113. South America Gene Editing Safety Assessment Services Consumption Value by Type (2021-2026) & (USD Million)
Table 114. South America Gene Editing Safety Assessment Services Consumption Value by Type (2027-2032) & (USD Million)
Table 115. South America Gene Editing Safety Assessment Services Consumption Value by Application (2021-2026) & (USD Million)
Table 116. South America Gene Editing Safety Assessment Services Consumption Value by Application (2027-2032) & (USD Million)
Table 117. South America Gene Editing Safety Assessment Services Consumption Value by Country (2021-2026) & (USD Million)
Table 118. South America Gene Editing Safety Assessment Services Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Type (2021-2026) & (USD Million)
Table 120. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Type (2027-2032) & (USD Million)
Table 121. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Application (2021-2026) & (USD Million)
Table 122. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Application (2027-2032) & (USD Million)
Table 123. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Country (2021-2026) & (USD Million)
Table 124. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value by Country (2027-2032) & (USD Million)
Table 125. Global Key Players of Gene Editing Safety Assessment Services Upstream (Raw Materials)
Table 126. Global Gene Editing Safety Assessment Services Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Gene Editing Safety Assessment Services Picture
Figure 2. Global Gene Editing Safety Assessment Services Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Gene Editing Safety Assessment Services Consumption Value Market Share by Type in 2025
Figure 4. Discovery Screening
Figure 5. Lead Optimization
Figure 6. Preclinical Development
Figure 7. IND-Enabling Studies
Figure 8. Clinical Development
Figure 9. Commercial and Lifecycle Support
Figure 10. Global Gene Editing Safety Assessment Services Consumption Value by Primary Technology Platform, (USD Million), 2021 & 2025 & 2032
Figure 11. Global Gene Editing Safety Assessment Services Consumption Value Market Share by Primary Technology Platform in 2025
Figure 12. In Silico Risk Prediction
Figure 13. Targeted Amplicon Sequencing
Figure 14. Genome-Wide Sequencing
Figure 15. Cytogenetic and Functional Assays
Figure 16. Unbiased Break-Site Mapping
Figure 17. Global Gene Editing Safety Assessment Services Consumption Value by Sample Source, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Gene Editing Safety Assessment Services Consumption Value Market Share by Sample Source in 2025
Figure 19. Established Cell Lines
Figure 20. Primary Somatic Cells
Figure 21. Stem and Progenitor Cells
Figure 22. Animal Tissues
Figure 23. Clinical Specimens
Figure 24. Other Biological Samples
Figure 25. Global Gene Editing Safety Assessment Services Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 26. Gene Editing Safety Assessment Services Consumption Value Market Share by Application in 2025
Figure 27. Biopharmaceutical and Cell & Gene Therapy Companies Picture
Figure 28. Clinical and Independent Testing Laboratories Picture
Figure 29. Academic and Government Research Institutes Picture
Figure 30. Agricultural Biotechnology Companies Picture
Figure 31. Industrial Biotechnology Companies Picture
Figure 32. Global Gene Editing Safety Assessment Services Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 33. Global Gene Editing Safety Assessment Services Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 34. Global Market Gene Editing Safety Assessment Services Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 35. Global Gene Editing Safety Assessment Services Consumption Value Market Share by Region (2021-2032)
Figure 36. Global Gene Editing Safety Assessment Services Consumption Value Market Share by Region in 2025
Figure 37. North America Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 38. Europe Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 39. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 40. South America Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 41. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 42. Company Three Recent Developments and Future Plans
Figure 43. Global Gene Editing Safety Assessment Services Revenue Share by Players in 2025
Figure 44. Gene Editing Safety Assessment Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 45. Market Share of Gene Editing Safety Assessment Services by Player Revenue in 2025
Figure 46. Top 3 Gene Editing Safety Assessment Services Players Market Share in 2025
Figure 47. Top 6 Gene Editing Safety Assessment Services Players Market Share in 2025
Figure 48. Global Gene Editing Safety Assessment Services Consumption Value Share by Type (2021-2026)
Figure 49. Global Gene Editing Safety Assessment Services Market Share Forecast by Type (2027-2032)
Figure 50. Global Gene Editing Safety Assessment Services Consumption Value Share by Application (2021-2026)
Figure 51. Global Gene Editing Safety Assessment Services Market Share Forecast by Application (2027-2032)
Figure 52. North America Gene Editing Safety Assessment Services Consumption Value Market Share by Type (2021-2032)
Figure 53. North America Gene Editing Safety Assessment Services Consumption Value Market Share by Application (2021-2032)
Figure 54. North America Gene Editing Safety Assessment Services Consumption Value Market Share by Country (2021-2032)
Figure 55. United States Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 56. Canada Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 57. Mexico Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 58. Europe Gene Editing Safety Assessment Services Consumption Value Market Share by Type (2021-2032)
Figure 59. Europe Gene Editing Safety Assessment Services Consumption Value Market Share by Application (2021-2032)
Figure 60. Europe Gene Editing Safety Assessment Services Consumption Value Market Share by Country (2021-2032)
Figure 61. Germany Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 62. France Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 63. United Kingdom Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 64. Russia Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 65. Italy Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 66. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value Market Share by Type (2021-2032)
Figure 67. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value Market Share by Application (2021-2032)
Figure 68. Asia-Pacific Gene Editing Safety Assessment Services Consumption Value Market Share by Region (2021-2032)
Figure 69. China Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 70. Japan Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 71. South Korea Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 72. India Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 73. Southeast Asia Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 74. Australia Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 75. South America Gene Editing Safety Assessment Services Consumption Value Market Share by Type (2021-2032)
Figure 76. South America Gene Editing Safety Assessment Services Consumption Value Market Share by Application (2021-2032)
Figure 77. South America Gene Editing Safety Assessment Services Consumption Value Market Share by Country (2021-2032)
Figure 78. Brazil Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 79. Argentina Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 80. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value Market Share by Type (2021-2032)
Figure 81. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value Market Share by Application (2021-2032)
Figure 82. Middle East & Africa Gene Editing Safety Assessment Services Consumption Value Market Share by Country (2021-2032)
Figure 83. Turkey Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 84. Saudi Arabia Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 85. UAE Gene Editing Safety Assessment Services Consumption Value (2021-2032) & (USD Million)
Figure 86. Gene Editing Safety Assessment Services Market Drivers
Figure 87. Gene Editing Safety Assessment Services Market Restraints
Figure 88. Gene Editing Safety Assessment Services Market Trends
Figure 89. Porters Five Forces Analysis
Figure 90. Gene Editing Safety Assessment Services Industrial Chain
Figure 91. Methodology
Figure 92. Research Process and Data Source